Patents Assigned to XWPHARMA LTD.
-
Patent number: 11944597Abstract: Pharmaceutical compositions comprising an immediate release component comprising 4-((L-valyl)oxy)butanoic acid and a modified release component comprising 4-((L-valyl)oxy)butanoic acid and the pharmacokinetics of 4-((L-valyl)oxy)butanoic acid and ?-hydroxybutyrate following oral administration of the pharmaceutical compositions is disclosed.Type: GrantFiled: October 26, 2022Date of Patent: April 2, 2024Assignee: XWPHARMA LTD.Inventors: Daniel M. Canafax, William W. Xiang, Leonard Blum, Jia-Ning Xiang
-
Patent number: 11925710Abstract: Pharmaceutical granulations having a functional coating surrounding a core containing 4-((L-valyl)oxy)butanoic acid are disclosed. The functional coatings provide for immediate release or modified release of 4-((L-valyl)oxy)butanoic acid. The pharmaceutical granulations can be used in oral pharmaceutical compositions.Type: GrantFiled: June 17, 2022Date of Patent: March 12, 2024Assignee: XWPHARMA LTD.Inventors: Sami Karaborni, Daniel M. Canafax, Jia-Ning Xiang, William W. Xiang, James Tien, Stefanie Thiel, Norbert Pollinger, Annette Grave
-
Patent number: 11905247Abstract: The present invention relates compounds of Formula (A) as NK-1 receptor antagonists, as well as their preparation and uses, and further relates pharmaceutical compositions comprising these compounds and their uses as modulators of dysfunctional glutamate transmission. The present invention also relates to the uses of the compounds or pharmaceutical compositions in treating or preventing certain disorders and diseases which relate to NK-1 receptor in humans. More specifically, the compounds and/or pharmaceutical compositions of the present invention are believed to potentially offer therapeutic benefits to patients who suffer, among others, chemotherapy-induced nausea and vomit (CINV) and/or post-operative nausea and vomit (PONV).Type: GrantFiled: September 15, 2021Date of Patent: February 20, 2024Assignee: XWPHARMA LTD.Inventors: Jia-Ning Xiang, Xuesong Xu, Yi Feng, Xianbo Liu, Wai-Si Eng
-
Patent number: 11896573Abstract: Pharmaceutical compositions of 4-((L-valyl)oxy)butanoic acid and the pharmacokinetics of 4-((L-valyl)oxy)butanoic acid and ?-hydroxybutyric acid following oral administration of the pharmaceutical compositions to healthy subjects are disclosed.Type: GrantFiled: July 22, 2021Date of Patent: February 13, 2024Assignee: XWPHARMA LTD.Inventors: William W. Xiang, Jia-Ning Xiang, Daniel M. Canafax
-
Patent number: 11767313Abstract: Nuclear transport modulators are disclosed. The compounds can inhibit nuclear transporters such as the exportin-1 transporter. The compounds and pharmaceutical compositions comprising the compounds can be used to treat neurological diseases and cancer.Type: GrantFiled: December 4, 2020Date of Patent: September 26, 2023Assignee: XWPHARMA LTD.Inventors: Jia-Ning Xiang, Zude Qi, Xianbo Liu, Dezheng Ning
-
Patent number: 11746081Abstract: The present disclosure is directed synthetic methods for the preparation of 4-valyloxybutyric acid. The synthetic methods described herein employ a diverse array of protecting group strategies and reaction conditions. Additionally, the present disclosure is directed to compounds useful as synthetic intermediates in the preparation of 4-valyloxybutyric acid.Type: GrantFiled: February 16, 2022Date of Patent: September 5, 2023Assignee: XWPHARMA LTD.Inventors: Jia-Ning Xiang, Hao-Wei Shih, Xiaoming Wu, Xuan Zhang, James Tien
-
Patent number: 11690811Abstract: Pharmaceutical compositions of ketamine derivatives and oral dosage forms comprising the pharmaceutical compositions are disclosed. Solid oral dosage forms prepared from the pharmaceutical compositions exhibit a zero-order release profile.Type: GrantFiled: August 12, 2022Date of Patent: July 4, 2023Assignee: XWPHARMA LTD.Inventors: Sami Karaborni, Daniel M. Canafax, William W. Xiang, Jia-Ning Xiang
-
Patent number: 11692008Abstract: Compounds of Formula (I)a or (I)b: including certain quinone derivatives, and the corresponding pharmaceutical compositions, which may serve to modulate ferroptosis in a subject. Also disclosed herein are the preparations of these compounds and pharmaceutical compositions and their potential uses in the manufacture of a medicament in reducing reactive oxygen species (ROS) in a cell and for preventing, treating, ameliorating certain related disorder or a disease.Type: GrantFiled: November 2, 2020Date of Patent: July 4, 2023Assignee: XWPHARMA LTD.Inventors: Jia-Ning Xiang, Zude Qi, Dezheng Ning, Xianbo Liu
-
Patent number: 11639337Abstract: The present invention relates compounds of Formula (A), as well as their preparation and uses, and further relates pharmaceutical compositions comprising these compounds and their uses as modulators of dysfunctional glutamate transmission. The present invention also relates to uses of the compounds or pharmaceutical compositions in treating or preventing certain neurological and psychiatric disorders and diseases as well as cancer in humans.Type: GrantFiled: June 8, 2022Date of Patent: May 2, 2023Assignee: XWPHARMA LTD.Inventors: Jia-Ning Xiang, Xuesong Xu, Wei Zhou
-
Patent number: 11510892Abstract: Pharmaceutical compositions comprising an immediate release component comprising 4-((L-valyl)oxy)butanoic acid and a modified release component comprising 4-((L-valyl)oxy)butanoic acid and the pharmacokinetics of 4-((L-valyl)oxy)butanoic acid and ?-hydroxybutyrate following oral administration of the pharmaceutical compositions is disclosed.Type: GrantFiled: March 18, 2022Date of Patent: November 29, 2022Assignee: XWPHARMA LTD.Inventors: Daniel M. Canafax, William W. Xiang, Leonard Blum, Jia-Ning Xiang
-
Patent number: 11440874Abstract: Ketamine derivatives and pharmaceutical compositions thereof are disclosed. When administered orally the ketamine derivatives provide increased bioavailability of ketamine in the systemic circulation. The ketamine derivatives can be used to treat neurological diseases, psychological diseases and pain.Type: GrantFiled: October 12, 2020Date of Patent: September 13, 2022Assignee: XWPHARMA LTD.Inventors: Jia-Ning Xiang, Xuesong Xu, Hao-Wei Shih, Wai-Si Eng
-
Patent number: 11420955Abstract: The present invention relates compounds of Formula (A) as H3R antagonists, as well as their preparation and uses, and further relates pharmaceutical compositions comprising these compounds and their uses as modulators of Histamine 3 Receptor (H3R) functions. The present invention also relates to the uses of the compounds or pharmaceutical compositions in treating or preventing certain disorders and diseases which relate to H3R functions in humans.Type: GrantFiled: March 5, 2021Date of Patent: August 23, 2022Assignee: XWPHARMA LTD.Inventors: Jia-Ning Xiang, Xuesong Xu, Yi Feng, Wai-Si Eng
-
Patent number: 11401249Abstract: The present invention relates compounds of Formula (A), as well as their preparation and uses, and further relates pharmaceutical compositions comprising these compounds and their uses as modulators of dysfunctional glutamate transmission. The present invention also relates to uses of the compounds or pharmaceutical compositions in treating or preventing certain neurological and psychiatric disorders and diseases as well as cancer in humans.Type: GrantFiled: October 29, 2020Date of Patent: August 2, 2022Assignee: XWPHARMA LTD.Inventors: Jia-Ning Xiang, Xuesong Xu, Wei Zhou
-
Patent number: 11395801Abstract: Pharmaceutical granulations having a functional coating surrounding a core containing 4-((L-valyl)oxy)butanoic acid are disclosed. The functional coatings provide for immediate release or modified release of 4-((L-valyl)oxy)butanoic acid. The pharmaceutical granulations can be used in oral pharmaceutical compositions.Type: GrantFiled: October 5, 2021Date of Patent: July 26, 2022Assignee: XWPHARMA LTD.Inventors: Sami Karaborni, Daniel M. Canafax, Jia-Ning Xiang, William W. Xiang, James Tien, Stefanie Thiel, Norbert Pollinger, Annette Grave
-
Patent number: 11357734Abstract: Granulations with granules having a high loading of an active pharmaceutical ingredient are disclosed. The active pharmaceutical ingredient has a high aqueous water solubility. The granules have a narrow particle size distribution and a smooth exterior surface.Type: GrantFiled: June 17, 2021Date of Patent: June 14, 2022Assignee: XWPHARMA LTD.Inventors: Sami Karaborni, William W. Xiang, Daniel M. Canafax, Jia-Ning Xiang
-
Patent number: 11312703Abstract: A compound of Formula (I), pharmaceutically acceptable salts thereof, and individual enantiomers or diastereomers thereof. Compositions and methods useful for treatment or suppression of diseases, developmental delays and symptoms related to oxidative stress.Type: GrantFiled: November 12, 2020Date of Patent: April 26, 2022Assignee: XWPHARMA LTD.Inventors: Jia-Ning Xiang, Zude Qi, Dezheng Ning, Xianbo Liu
-
Patent number: 11304906Abstract: Pharmaceutical granulations having a functional coating surrounding a core containing a water-soluble active pharmaceutical ingredient are disclosed. The functional coating provides for immediate release or controlled release of the active pharmaceutical ingredient. The pharmaceutical granulations can be used in oral pharmaceutical compositions.Type: GrantFiled: June 17, 2021Date of Patent: April 19, 2022Assignee: XWPHARMA LTD.Inventors: Sami Karaborni, Daniel M. Canafax, Jia-Ning Xiang, William W. Xiang, James Tien, Nicolas D. Kirkland
-
Patent number: 11279669Abstract: The present disclosure is directed synthetic methods for the preparation of 4-valyloxybutyric acid. The synthetic methods described herein employ a diverse array of protecting group strategies and reaction conditions. Additionally, the present disclosure is directed to compounds useful as synthetic intermediates in the preparation of 4-valyloxybutyric acid.Type: GrantFiled: June 18, 2021Date of Patent: March 22, 2022Assignee: XWPHARMA LTD.Inventors: Jia-Ning Xiang, Hao-Wei Shih, Xiaoming Wu, Xuan Zhang, James Tien
-
Patent number: 11149006Abstract: The present invention relates compounds of Formula (A) as NK-1 receptor antagonists, as well as their preparation and uses, and further relates pharmaceutical compositions comprising these compounds and their uses as modulators of dysfunctional glutamate transmission. The present invention also relates to the uses of the compounds or pharmaceutical compositions in treating or preventing certain disorders and diseases which relate to NK-1 receptor in humans. More specifically, the compounds and/or pharmaceutical compositions of the present invention are believed to potentially offer therapeutic benefits to patients who suffer, among others, chemotherapy-induced nausea and vomit (CINV) and/or post-operative nausea and vomit (PONV).Type: GrantFiled: March 6, 2020Date of Patent: October 19, 2021Assignee: XWPHARMA LTD.Inventors: Jia-Ning Xiang, Xuesong Xu, Yi Feng, Xianbo Liu, Wai-Si Eng